PAPI, Alberto
 Distribuzione geografica
Continente #
NA - Nord America 26.716
EU - Europa 6.300
AS - Asia 3.471
OC - Oceania 22
SA - Sud America 18
Continente sconosciuto - Info sul continente non disponibili 15
AF - Africa 9
Totale 36.551
Nazione #
US - Stati Uniti d'America 26.694
CN - Cina 2.257
UA - Ucraina 1.747
IT - Italia 1.107
TR - Turchia 993
DE - Germania 869
GB - Regno Unito 758
NL - Olanda 484
SE - Svezia 472
FI - Finlandia 392
PL - Polonia 149
FR - Francia 114
VN - Vietnam 92
BE - Belgio 75
AT - Austria 34
IN - India 33
TW - Taiwan 19
AU - Australia 18
CA - Canada 17
JP - Giappone 16
EU - Europa 13
HK - Hong Kong 13
RU - Federazione Russa 13
ES - Italia 12
IE - Irlanda 12
IR - Iran 10
BR - Brasile 9
CH - Svizzera 9
KR - Corea 9
PT - Portogallo 9
RO - Romania 9
CZ - Repubblica Ceca 8
GR - Grecia 8
MK - Macedonia 6
EG - Egitto 5
TH - Thailandia 5
MX - Messico 4
NZ - Nuova Zelanda 4
PK - Pakistan 4
ID - Indonesia 3
LA - Repubblica Popolare Democratica del Laos 3
MY - Malesia 3
RS - Serbia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
CL - Cile 2
HR - Croazia 2
HU - Ungheria 2
IL - Israele 2
PE - Perù 2
SG - Singapore 2
SK - Slovacchia (Repubblica Slovacca) 2
VE - Venezuela 2
AL - Albania 1
AR - Argentina 1
BO - Bolivia 1
BY - Bielorussia 1
CO - Colombia 1
HN - Honduras 1
IQ - Iraq 1
KE - Kenya 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
NG - Nigeria 1
NO - Norvegia 1
PH - Filippine 1
SA - Arabia Saudita 1
TN - Tunisia 1
UZ - Uzbekistan 1
Totale 36.551
Città #
Fairfield 4.047
Woodbridge 3.629
Houston 2.610
Jacksonville 2.032
Ashburn 1.809
Chandler 1.631
Seattle 1.488
Wilmington 1.427
Ann Arbor 1.326
Cambridge 1.316
Izmir 696
Nanjing 628
Princeton 564
San Diego 364
Beijing 305
Ferrara 301
Boardman 280
Washington 232
Nanchang 192
Milan 168
Shenyang 165
New York 159
Warsaw 146
Addison 131
Hebei 124
Tianjin 124
Dearborn 108
London 102
Changsha 101
Jiaxing 100
Shanghai 99
Dong Ket 90
Mountain View 86
Falls Church 79
Brussels 74
Redwood City 74
Norwalk 66
Zhengzhou 59
Kunming 50
Bremen 49
Jinan 49
Ningbo 45
Orange 45
Chicago 39
Guangzhou 39
San Mateo 36
Auburn Hills 31
Taizhou 31
Verona 29
Lanzhou 27
Des Moines 26
Bologna 25
Helsinki 24
Philadelphia 24
Paris 23
Vienna 22
Rome 21
Los Angeles 20
Changchun 19
Hangzhou 19
Tappahannock 18
Indiana 15
Kilburn 15
Redmond 15
Augusta 14
Hounslow 14
Munich 14
Hefei 13
Ferrara di Monte Baldo 12
Napoli 11
Pordenone 11
Chiswick 10
Islington 10
Oristano 10
Taipei 10
Acton 9
Walnut 9
Brno 8
Catania 8
Florence 8
Leawood 8
Wuhan 8
Edinburgh 7
Fuzhou 7
Monmouth Junction 7
Padova 7
Dallas 6
Dublin 6
Haikou 6
Prescot 6
San Francisco 6
Taiyuan 6
Torino 6
Yokohama 6
Lappeenranta 5
New Delhi 5
Toronto 5
Turin 5
Ardabil 4
Delebio 4
Totale 27.979
Nome #
Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program 562
Value of fiberoptic bronchoscopy in addition to 18F-FDG-PET/CT in the differentiation of solitary pulmonary nodules: a prospective study 291
Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations 257
Severe pneumonia after intravesical BCG instillation in a patient with invasive bladder cancer: case report and literature review 171
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial 163
An official American Thoracic Society/European Respiratory Society statement: research questions in COPD 160
Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD 153
Polmonite da ipersensibilità da antigeni aviari in un italiano adulto 146
Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma 143
Echocardiography, Spirometry, and Systemic Acute-Phase Inflammatory Proteins in Smokers with COPD or CHF: An Observational Study 140
COPD: early diagnosis and treatment to slow disease progression 135
Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells 135
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial 134
Oxygen radical scavengers inhibit clastogenic activity induced by sonication of human serum 133
Inhaled corticosteroid/long-acting bronchodilator treatment mitigates STEMI clinical presentation in COPD patients 131
Endothelial dysfunction and increased platelet reactivity in patients with acute coronary syndrome and undiagnosed COPD: insights into the SCAP trial 131
Chronic Obstructive Pulmonary Disease and Ischemic Heart Disease Comorbidity: Overview of Mechanisms and Clinical Management 129
Predischarge screening for chronic obstructive pulmonary disease in patients with acute coronary syndrome and smoking history 128
Models of infection and exacerbations in COPD. 127
Malattie polmonari primitive da cause dismetaboliche. 127
Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations 127
INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. 126
Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: A pooled analysis. 126
COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma 126
Deficient antiviral immune responses in childhood: Distinct roles of atopy and asthma 124
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial 123
Rhinovirus vaccination: the case against 122
Effect of subchronic in vivo exposure to nitrogen dioxide on lung tissue inflammation, airway microvascular leakage, and in vitro bronchial muscle responsiveness in rats 121
null 121
Management of bronchial asthma 120
Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomised, double-blind clinical trial 120
Primary pulmonary epithelioid hemangioendothelioma: A rare cause of PET-negative pulmonary nodules 120
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial 119
Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS. 118
null 118
Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma. 117
null 117
Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease 116
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease 116
Role of Stem Cells in the Pathogenesis of COPD and Pulmonary Emphysema 115
Immune Response to Mycobacterium tuberculosis Infection in the Parietal Pleura of Patients with Tuberculous Pleurisy 115
Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up 115
null 114
Combination treatment in asthma: Reviewing old and new options 114
Emphysema contribution to the progression of chronic obstructive pulmonary disease. 112
Extrafine beclometasone diproprionate/formoterol fumarate: A review of its effects in chronic obstructive pulmonary disease 112
null 111
Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation 111
Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. 111
Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production 110
Slower rise of exhaled breath temperature in chronic obstructive pulmonary disease 110
Mechanisms of rhinovirus-induced asthma. 110
Interleukin-13 and-4 expression in the central airways of smokers with chronic bronchitis 109
ALTERATION OF ADENOSINE RECEPTORS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 109
Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis 109
Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD 109
Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma 109
Airway inflammation and illness severity in response to experimental rhinovirus infection in asthma. 108
B Cell Activating Factor (BAFF) Is Expressed by Lymphoid Follicles of COPD Patients 107
Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial 107
Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. 107
Mechanisms of corticosteroid resistance in severe asthma and chronic obstructive pulmonary disease (COPD) 106
COPD exacerbations: definitions and classifications 105
Clinical definition of COPD exacerbations and classification of their severity 104
Reducing agents inhibit rhinovirus-induced up-regulation of the rhinovirus receptor intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells 104
Extrafine beclomethasone dipropionate/formoterol hydrofluoroalkane-propelled inhaler in asthma. 104
Management of patients with early mild asthma and infrequent symptoms 104
A human rhinovirus model of chronic obstructive pulmonary disease exacerbations 103
Unbalanced oxidant-induced DNA damage and repair in COPD: A link towards lung cancer 103
Increased expression of aquaporin 5 in bronchial glands of smokers with or without COPD 103
Phospho-p38 MAPK expression in COPD patients and asthmatics and in challenged bronchial epithelium 103
Bronchopulmonary inflammation and airway smooth muscle hyperresponsiveness induced by nitrogen dioxide in guinea pigs 103
The future of relievers and controllers in asthma therapy. 103
Protection of erdosteine on smoke‐induced peripheral neutrophil dysfunction both in healthy and in bronchitic smokers 102
Oxidants in asthma and in chronic obstructive pulmonary disease (COPD) 102
T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. 102
Step-down from high dose fixed combination therapy in asthma patients: a randomized controlled trial. 102
null 102
Reducing Agents Decrease the Oxidative Burst and Improve Clinical Outcomes in COPD Patients: A Randomised Controlled Trial on the Effects of Sulphurous Thermal Water Inhalation. 102
Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study 102
AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation 102
Recent thymic emigrants do not account for the increased number of T-cells seen in the lungs of stable chronic obstructive pulmonary disease 101
Respiratory virus induction of alpha-, beta- and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. 101
Short term efficacy of nebulized beclomethasone in mild-to-moderate wheezing episodes in pre-school children 101
Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD. 101
A valid option for asthma control: Clinical evidence on efficacy and safety of fluticasone propionate/formoterol combination in a single inhaler 101
Near-fatal asthma phenotype in the ENFUMOSA Cohort. 100
IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease 100
Prevention of COPD exacerbations: A European Respiratory Society/ American Thoracic Society guideline 100
Exacerbations of asthma and chronic obstructive pulmonary disease (COPD): focus on virus induced exacerbations. 100
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline 100
Mechanisms involved in lung cancer development in COPD 99
Severe asthma: pragmatic clinical lumping and time for investigational splitting. 99
IFN-alpha/IFN-lambda responses to respiratory viruses in paediatric asthma 99
The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics 98
Inhaler devices for asthma: A call for action in a neglected field 98
Circulating endothelial stem cells are not decreased in pulmonary emphysema or COPD 98
Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: Evidence and future perspectives 98
Small airway disease in asthma: pathophysiological and diagnostic considerations 97
Increased activation of p38 MAPK in COPD 97
Totale 12.176
Categoria #
all - tutte 136.621
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 6.388
Totale 143.009


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20194.416 0 0 0 0 0 0 0 38 424 897 1.083 1.974
2019/20209.055 1.384 281 356 1.346 666 1.283 806 959 737 752 289 196
2020/20216.478 437 479 305 731 321 681 279 751 170 784 881 659
2021/20225.146 219 452 320 258 197 236 283 293 204 380 461 1.843
2022/20234.281 575 103 145 491 619 645 194 402 542 71 325 169
2023/20241.394 259 275 121 92 179 279 78 111 0 0 0 0
Totale 37.511